1.1.1.41 130-nucleotide transcript containing the 5'-untranslated regions of the yeast mitochondrial COX2 mRNA inhibition with a 50% reduction in activity observed with 40 nM mRNA 132236 1.1.1.41 2-hydroxyethylamine-N,N-diacetate - 91058 1.1.1.41 2-oxoglutarate - 34 1.1.1.41 2-oxoglutarate strong inhibition at 10 mM 34 1.1.1.41 2-oxoglutarate complete inhibition at 10 mM 34 1.1.1.41 2-Oxopropane-1,1,3-tricarboxylate only in presence of ADP 91171 1.1.1.41 ADP 10 mM 13 1.1.1.41 ADP 85% residual activity at 2 mM 13 1.1.1.41 ADP 86.63% residual activity at 1 mM 13 1.1.1.41 AMP 79% residual activity at 2 mM 30 1.1.1.41 AMP 97.88% residual activity at 1 mM 30 1.1.1.41 ATP - 4 1.1.1.41 ATP 10 mM 4 1.1.1.41 ATP strong inhibition at 10 mM 4 1.1.1.41 ATP 68% residual activity at 2 mM 4 1.1.1.41 ATP 88.7% residual activity at 1 mM 4 1.1.1.41 beta-mercapto-alpha-ketoglutarate inhibition in presence and absence of AMP, competitive inhibition 105575 1.1.1.41 bilirubin - 599 1.1.1.41 Ca2+ - 15 1.1.1.41 Ca2+ complete inhibition at 2 mM 15 1.1.1.41 Ca2+ 1.9% residual activity at 2 mM 15 1.1.1.41 Ca2+ 7.9% residual activity at 2 mM 15 1.1.1.41 Ca2+ 3.87% residual activity at 2 mM 15 1.1.1.41 Ca2+ complete inhibition at 2 mM (pH 6.0) 15 1.1.1.41 Chicago sky blue - 92890 1.1.1.41 cis-aconitate 91% residual activity at 2 mM 1230 1.1.1.41 citrate - 131 1.1.1.41 citrate with constant concentrations of isocitrate, NAD+ and Mg2+ up to 10 mM and without AMP, citrate is an activator 131 1.1.1.41 citrate 10 mM 131 1.1.1.41 Cl- 100 mM 141 1.1.1.41 CN- - 159 1.1.1.41 Co2+ - 23 1.1.1.41 Co2+ 8.7% residual activity at 2 mM 23 1.1.1.41 Co2+ 5.2% residual activity at 2 mM 23 1.1.1.41 Co2+ 5.96% residual activity at 2 mM 23 1.1.1.41 Congo red - 7171 1.1.1.41 Cu2+ complete inhibition 19 1.1.1.41 Cu2+ - 19 1.1.1.41 Cu2+ complete inhibition at 2 mM 19 1.1.1.41 Cu2+ 1.3% residual activity at 2 mM 19 1.1.1.41 Cu2+ 5.76% residual activity at 2 mM 19 1.1.1.41 Cu2+ complete inhibition at 2 mM (pH 6.0) 19 1.1.1.41 D,L-hibiscusate with constant concentrations of isocitrate, NAD+ and Mg2+ up to 10 mM and without AMP, D,L-hibiscusate is an activator 105795 1.1.1.41 D,L-threo-alpha-methylisocitrate inhibition in presence and absence of AMP, competitive inhibition 105797 1.1.1.41 D-malate inhibition only in absence of AMP 1139 1.1.1.41 D-Tartrate inhibition only in absence of AMP 7181 1.1.1.41 Diamide treatment of the affinity-purified enzyme with diamide results in the formation of disulfide bonds and in decreased activity for the wild type enzyme, the effect is reversible by the addition of dithiothreitol 2482 1.1.1.41 Diamide increases disulfide content of the enzyme 2482 1.1.1.41 EDTA - 21 1.1.1.41 EGTA - 173 1.1.1.41 fluorescein halogenated derivatives 12530 1.1.1.41 Fluorocitrate with constant concentrations of isocitrate, NAD+ and Mg2+ up to 10 mM and without AMP, fluorocitrate is an activator 4813 1.1.1.41 fumarate inhibition only in absence of AMP 170 1.1.1.41 fumarate 96% residual activity at 2 mM 170 1.1.1.41 gamma-aminobutyric acid slight inhibition 7196 1.1.1.41 glutamate slight inhibition 297 1.1.1.41 glyoxylate with oxaloacetate, concomitantly added 101 1.1.1.41 glyoxylate - 101 1.1.1.41 glyoxylate slight inhibition 101 1.1.1.41 homocitrate inhibition only in absence of AMP 21232 1.1.1.41 I- 100 mM 507 1.1.1.41 K+ 1.7% residual activity at 2 mM 39 1.1.1.41 K+ complete inhibition at 2 mM 39 1.1.1.41 K+ 4.12% residual activity at 2 mM 39 1.1.1.41 L-garciniate inhibition in presence and absence of AMP 106397 1.1.1.41 L-glutamate - 41 1.1.1.41 L-glutamate 90% residual activity at 2 mM 41 1.1.1.41 L-glutamine 96% residual activity at 2 mM 102 1.1.1.41 L-hibiscusate with constant concentrations of isocitrate, NAD+ and Mg2+ up to 10 mM and without AMP, L-hibiscusate is an activator 106409 1.1.1.41 L-malate inhibition only in absence of AMP, competitive inhibition 247 1.1.1.41 L-Tartrate inhibition only in absence of AMP 1874 1.1.1.41 Li+ 5.15% residual activity at 2 mM 152 1.1.1.41 Maleate inhibition only in absence of AMP 575 1.1.1.41 malonate inhibition only in absence of AMP 392 1.1.1.41 Mg2+ free form 6 1.1.1.41 mitochondrial COX2 UTR RNA - 106558 1.1.1.41 molybdate - 509 1.1.1.41 additional information the enzyme is not affected by NADP+, HCO3-, and 2-oxoglutarate 2 1.1.1.41 additional information enzyme is not affected by gamma-aminobutyric acid and glutamate 2 1.1.1.41 additional information no inhibition by NADPH and citrate 2 1.1.1.41 additional information not influenced by pyruvate and malate 2 1.1.1.41 additional information not inhibited by 2-oxoglutarate 2 1.1.1.41 additional information the enzyme is unaffected by the addition of 5 mM L-glutamate, L-glutamine, 2-oxoglutarate, oxaloacetate, cis-aconitate, citrate, pyruvate, malate, fumarate, succinate, CoA, AcCoA, NADH, and NADPH or 2 mM ADP and AMP 2 1.1.1.41 mRNA enzyme specifically binds to 5'-untranslated regions of yeast mitochondrial mRNAs, and transcripts containing these regions allosterically inhibit the enzyme, which can be relieved by activator AMP in presence of isocitrate, complex formation, overview 7378 1.1.1.41 N3- - 582 1.1.1.41 Na+ 3.2% residual activity at 2 mM 59 1.1.1.41 Na+ complete inhibition at 2 mM 59 1.1.1.41 Na+ 4.66% residual activity at 2 mM 59 1.1.1.41 NADH - 8 1.1.1.41 NADH competitive inhibitor 8 1.1.1.41 NADH inhibits ICDH-2 8 1.1.1.41 NADH complete inhibition at 0.2 mM, competitive 8 1.1.1.41 NADH competitive 8 1.1.1.41 NADH comptitive with respect to NAD+ 8 1.1.1.41 NADH NADH can compete with NAD+ to bind to the active site and inhibits the activity of the alphabeta heterodimer 8 1.1.1.41 NADH NADH at the active site occupies the binding site for NAD+ and prevents the binding of the cofactor. NADH at the allosteric site occupies the binding sites for ADP and citrate and blocks the binding of the activators. NADH inhibits the activities of the alphagamma, alphabeta and alpha2betagamma enzyme forms 8 1.1.1.41 NADPH - 5 1.1.1.41 NADPH noncompetitive inhibitor 5 1.1.1.41 NADPH noncompetitive 5 1.1.1.41 Ni2+ - 38 1.1.1.41 Ni2+ 4.4% residual activity at 2 mM 38 1.1.1.41 Ni2+ complete inhibition at 2 mM 38 1.1.1.41 Ni2+ 1.6% residual activity at 2 mM 38 1.1.1.41 nitrilotriacetate - 4548 1.1.1.41 NO3- 100 mM 673 1.1.1.41 oxaloacetate - 57 1.1.1.41 oxaloacetate slight inhibition 57 1.1.1.41 oxaloacetate 98% residual activity at 2 mM 57 1.1.1.41 p-hydroxymercuribenzoate - 98 1.1.1.41 pyruvate with oxaloacetate, concomitantly added, less effective than glyoxylate + oxaloacetate 31 1.1.1.41 succinate inhibition only in absence of AMP 58 1.1.1.41 succinate slight inhibition 58 1.1.1.41 succinate 95% residual activity at 2 mM 58 1.1.1.41 Succinic semialdehyde slight inhibition 809 1.1.1.41 Sulfobromophthalein - 6595 1.1.1.41 thiocyanate - 931 1.1.1.41 tributyltin TBT, active in NT2/D1 carcinoma cells, overview. At nanomoler concentrations, tributyltin actions are mediated by genomic pathways via peroxisome proliferator-activated receptor gamma/retinoid X receptor, PPAR/RXR. Binding and in silico docking simulation analysis, overview 5717 1.1.1.41 Zn2+ complete inhibition 14 1.1.1.41 Zn2+ - 14 1.1.1.41 Zn2+ complete inhibition at 2 mM 14 1.1.1.41 Zn2+ 0.4% residual activity at 2 mM 14 1.1.1.41 Zn2+ NAD+-linked activity at pH 8.5 is strongly inhibited by Zn2+ but partially restored at pH 6.0 14